GlassScriptPhysician profile
Donna H Tran
NPI 1134301070
$1,358.34
in general payments reported to CMS, 2019-2025
20 companies · $340 in 2025
The $340 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $227 · 2022: $258 · 2023: $290 · 2024: $244 · 2025: $340.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $873.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $873.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intra-Sana Laboratories | $431.80 | 2022-2025 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| Amgen INC. | $196.49 | 2021-2025 | Evenity, Prolia |
| Novo Nordisk INC | $173.87 | 2021-2024 | Ozempic, Rybelsus |
| Dexcom, INC. | $106.48 | 2024-2025 | Dexcom G6 Transmitter |
| Gilead Sciences, INC. | $80.49 | 2021-2025 | |
| Phathom Pharmaceuticals, INC. | $42.74 | 2024-2025 | Voquezna |
| Regeneron Healthcare Solutions, INC. | $36.00 | 2022 | |
| Janssen Pharmaceuticals, INC | $33.49 | 2023 | Spravato |
| Abbvie INC. | $32.16 | 2021 | |
| Insulet Corporation | $31.56 | 2025 | Omnipod |
| Glaxosmithkline, LLC. | $24.94 | 2024 | Shingrix, Arexvy |
| Astrazeneca Pharmaceuticals LP | $23.39 | 2021 | |
| Eisai INC. | $22.18 | 2022 | |
| Almatica Pharma LLC | $22.16 | 2025 | Loreev Xr |
| Zimmer Biomet Holdings, INC. | $21.98 | 2024 | Gel-One Cross-Linked Hyaluronate |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $20.94 | 2025 | Gvoke Hypopen |
| Paratek Pharmaceuticals, INC. | $20.36 | 2024 | Nuzyra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.42 | 2022 | |
| Cequr Corporation | $14.20 | 2022 | |
| Bard Peripheral Vascular, INC. | $8.69 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donna Tran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.